XLO
Xilio Therapeutics, Inc.
Last earnings +0.0% on 2026-05-12
$9.27
▲ +2.43%$9.27▲ +0.32%
over 1Y
L $7.14EODHDH $12.08
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.4%
1W+3.7%
1M+12.4%
3M+12.6%
YTD-1.5%
1Y+0.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 5 analysts
Buy
Revenue grew 589.9% YoY; but unprofitable (net margin -80.1%).
Revenue (FY2025) $43.8M · FY2025
Xilio Therapeutics, Inc. shows $43.8M in FY2025 revenue (+589.9% YoY), a -80.1% net margin, and -99.3% ROE.
Supporting the case: revenue grew 589.9% YoY.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $6.34M | $43.8M |
| Gross profit | — | — | — | — | — |
| Operating income | -$75.0M | -$89.1M | -$79.1M | -$60.6M | -$42.0M |
| Net income | -$75.8M | -$88.2M | -$76.4M | -$58.2M | -$35.0M |
| Diluted EPS | -$13.52 | -$3.22 | -$2.78 | -$15.24 | -$4.19 |
| Net margin | — | — | — | -918.0% | -80.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$78.3M
EV / EBITDA—
EV / Sales-1.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-59.1%
FCF yield-9.3%
Quality & risk
ROIC (est.)-94.0%
Free cash flow-$5.51M
Total debt—
Net cash$138M
Altman Z-Score-3.42 distress
Piotroski F-Score5/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-88.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Officer / director change2026-06-12
- S-3/A Shelf registration (potential raise)2026-05-27
- 8-K Earnings results2026-05-12
- S-3 Shelf registration (potential raise)2026-05-12
- 10-Q Quarterly report2026-05-12
- DEF 14A Proxy statement2026-04-28
- 8-K Officer / director change2026-04-16
- 8-K Earnings results2026-03-23
- 10-K Annual report2026-03-23
Recent filings
all on EDGAR ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗8-KPeriod ending 2026-06-102026-06-12open ↗EFFECTFiling2026-05-29open ↗S-3/AFiling2026-05-27open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗
Frequently asked
- Is Xilio Therapeutics, Inc. (XLO) a buy?
- XLO currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 589.9% YoY; but unprofitable (net margin -80.1%).
- What is Xilio Therapeutics, Inc.'s quality score?
- XLO scores 58.50680330135279/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001840233, latest 10-Q filed 2026-05-12) · EODHD · as of 7/1/2026, 11:11:35 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.